Abstract
We have treated 61 children (51F, 10M) with central precocious puberty using intranasal (D-Ser6) GnRH analogue (Busorclin). Maximum duration of treatment was 3.7 yrs in the girls and 3.0 yrs in the boys. Mean dose (SD) of (D-Ser6) GnRH was 25.3 (9) μg/kg in the girls and 18.6 (12) μg/kg in the boys.
No side effects were seen. 5 patients stopped treatment due to non-compliance. Of 27 children who had puberty stage 2 - 3 before treatment, 20 arrested or regressed and 7 advanced. Of 21 children treated at stage 4 - 5, 7 regressed and 14 had no alteration. Mean testicular volume in the boys was reduced from 9.2 (6) mis to 5(1.4) mis after 1 year of treatment.
Mean basal serum LH became elevated during treatment, although there was a decrease in peak stimulated LH concentrations.
ΔBA/ΔCA fell during the first year of treatment to below 1.0. Height velocity in the girls reduced from 9.0 - 6.0 cms/yr during the second year of treatment. Height for bone age SDS increased from -1.86 (1.5) to -1.1 (1.5) during the first 1.5 yrs of treatment in the girls which was not significantly different from untreated controls.
Intranasal (D-Ser6) GnRH is an effective treatment for central precocious puberty but does not alter height prognosis.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brook, C. 134 INTRANASAL (D-Ser6) GnRH ANALOGUE FOR THE MANAGEMENT OF CENTRAL PRECOCIOUS PUBERTY. Pediatr Res 24, 539 (1988). https://doi.org/10.1203/00006450-198810000-00155
Issue Date:
DOI: https://doi.org/10.1203/00006450-198810000-00155